299 related articles for article (PubMed ID: 35354302)
1. Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials.
Dayyani M; Sadeghirad B; Grotta JC; Zabihyan S; Ahmadvand S; Wang Y; Guyatt GH; Amin-Hanjani S
Stroke; 2022 Jun; 53(6):1993-2005. PubMed ID: 35354302
[TBL] [Abstract][Full Text] [Related]
2. Effects of Various Therapeutic Agents on Vasospasm and Functional Outcome After Aneurysmal Subarachnoid Hemorrhage-Results of a Network Meta-Analysis.
Mishra S; Garg K; Gaonkar VB; Singh PM; Singh M; Suri A; Chandra PS; Kale SS
World Neurosurg; 2021 Nov; 155():41-53. PubMed ID: 34339892
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
Saber H; Desai A; Palla M; Mohamed W; Seraji-Bozorgzad N; Ibrahim M
J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):2979-2985. PubMed ID: 30093204
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness comparisons of drug therapies for postoperative aneurysmal subarachnoid hemorrhage patients: network meta‑analysis and systematic review.
Yu W; Huang Y; Zhang X; Luo H; Chen W; Jiang Y; Cheng Y
BMC Neurol; 2021 Jul; 21(1):294. PubMed ID: 34311705
[TBL] [Abstract][Full Text] [Related]
5. [Protective measures against cerebral ischemia following subarachnoid hemorrhage: Part 1].
Romero Kräuchi O; Verger Bennasar AM
Rev Esp Anestesiol Reanim; 2011 Apr; 58(4):230-5. PubMed ID: 21608279
[TBL] [Abstract][Full Text] [Related]
6. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients.
Endo H; Hagihara Y; Kimura N; Takizawa K; Niizuma K; Togo O; Tominaga T
J Neurosurg; 2022 Dec; 137(6):1707-1717. PubMed ID: 35364589
[TBL] [Abstract][Full Text] [Related]
7. Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study.
Muraoka S; Asai T; Fukui T; Ota S; Shimato S; Koketsu N; Nishizawa T; Araki Y; Saito R
Neurosurg Rev; 2023 Aug; 46(1):195. PubMed ID: 37555872
[TBL] [Abstract][Full Text] [Related]
8. Role of Cilostazol in Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage-A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Bohara S; Garg K; Singh Rajpal PM; Kasliwal M
World Neurosurg; 2021 Jun; 150():161-170. PubMed ID: 33631387
[TBL] [Abstract][Full Text] [Related]
9. Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials.
Wang X; Li YM; Li WQ; Huang CG; Lu YC; Hou LJ
PLoS One; 2012; 7(10):e47778. PubMed ID: 23082215
[TBL] [Abstract][Full Text] [Related]
10. Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage.
Mayer SA; Aldrich EF; Bruder N; Hmissi A; Macdonald RL; Viarasilpa T; Marr A; Roux S; Higashida RT
Stroke; 2019 Oct; 50(10):2738-2744. PubMed ID: 31394993
[TBL] [Abstract][Full Text] [Related]
11. Nicardipine Prolonged Release Implants for Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
Akbik F; Waddel H; Jaja BNR; Macdonald RL; Moore R; Samuels OB; Sadan O
J Stroke Cerebrovasc Dis; 2021 Oct; 30(10):106020. PubMed ID: 34365121
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.
Shan T; Zhang T; Qian W; Ma L; Li H; You C; Xie X
J Neurol; 2020 Jun; 267(6):1577-1584. PubMed ID: 30739182
[TBL] [Abstract][Full Text] [Related]
13. Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage.
Qureshi AI; Lobanova I; Huang W; Ishfaq MF; Broderick JP; Cassarly CN; Martin RH; Macdonald RL; Suarez JI
Neurocrit Care; 2022 Apr; 36(2):662-681. PubMed ID: 34940927
[TBL] [Abstract][Full Text] [Related]
14. An Update on the Efficacy and Safety Profile of Clazosentan in Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
Song J; Xue YQ; Wang YJ; Xu P; Sun DK; Chen W
World Neurosurg; 2019 Mar; 123():e235-e244. PubMed ID: 30496924
[TBL] [Abstract][Full Text] [Related]
15. An overview of pharmacotherapy for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage.
Maruhashi T; Higashi Y
Expert Opin Pharmacother; 2021 Aug; 22(12):1601-1614. PubMed ID: 33823726
[No Abstract] [Full Text] [Related]
16. Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.
Shen J; Pan JW; Fan ZX; Xiong XX; Zhan RY
J Neurosurg; 2013 Jul; 119(1):180-9. PubMed ID: 23641823
[TBL] [Abstract][Full Text] [Related]
17. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
Schmid-Elsaesser R; Kunz M; Zausinger S; Prueckner S; Briegel J; Steiger HJ
Neurosurgery; 2006 Jun; 58(6):1054-65; discussion 1054-65. PubMed ID: 16723884
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic magnesium for improving neurologic outcome after aneurysmal subarachnoid hemorrhage: systematic review and meta-analysis.
Golan E; Vasquez DN; Ferguson ND; Adhikari NK; Scales DC
J Crit Care; 2013 Apr; 28(2):173-81. PubMed ID: 23192249
[TBL] [Abstract][Full Text] [Related]
19. A network meta-analysis of therapeutic and prophylactic management of vasospasm on aneurysmal subarachnoid hemorrhage outcomes.
Chousterman B; Leclère B; Morisson L; Eude Y; Gayat E; Mebazaa A; Cinotti R
Front Neurol; 2023; 14():1217719. PubMed ID: 37662039
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Clazosentan After Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis.
Pontes JPM; Santos MDC; Gibram FC; Rodrigues NMV; Cavalcante-Neto JF; Barros ADM; Solla DJF
Neurosurgery; 2023 Dec; 93(6):1208-1219. PubMed ID: 37462365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
